|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5652338A
(en)
|
1988-03-16 |
1997-07-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Neutrophil chemotactic factor
|
|
ATE116366T1
(de)
|
1988-05-02 |
1995-01-15 |
Us Health |
Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
|
|
ATE113312T1
(de)
|
1988-08-29 |
1994-11-15 |
Us Gov Health & Human Serv |
Verfahren zur herstellung eines polypeptids welches als menschlicher neutrophiler chemotaktischer faktor aktiv ist.
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5427098A
(en)
|
1988-12-22 |
1995-06-27 |
Biofield Corp. |
Noninvasive method for determining treatment based upon lesion cell proliferation measurements
|
|
GB8909218D0
(en)
|
1989-04-22 |
1989-06-07 |
Medical Res Council |
Improvements in or relating to enhancers
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
IE913192A1
(en)
|
1990-09-12 |
1992-02-25 |
Scripps Research Inst |
Active site of interleukin-8: polypeptide analogs and¹antibodies
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
US5856457A
(en)
|
1991-03-29 |
1999-01-05 |
Genentech, Inc. |
Nucleic acids encoding a human IL-8 receptor
|
|
US5840856A
(en)
|
1991-03-29 |
1998-11-24 |
Genentech, Inc. |
Antibodies to a human PF4 superfamily receptor
|
|
DE69231223T3
(de)
|
1991-03-29 |
2008-01-17 |
Genentech, Inc., South San Francisco |
Menschliche pf4a rezeptoren und ihre verwendung
|
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
|
US5919896A
(en)
|
1991-03-29 |
1999-07-06 |
Genentech, Inc. |
PF4A receptor
|
|
US5776457A
(en)
|
1991-03-29 |
1998-07-07 |
Genentech, Inc. |
Antibodies to human PF4A receptor and compositions thereof
|
|
US6087475A
(en)
|
1991-12-19 |
2000-07-11 |
Genentech, Inc. |
PF4A receptor
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
US5508717A
(en)
|
1992-07-28 |
1996-04-16 |
Sony Corporation |
Computer pointing device with dynamic sensitivity
|
|
US6200558B1
(en)
|
1993-09-14 |
2001-03-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6448379B1
(en)
|
1993-09-14 |
2002-09-10 |
Chiron Corporation |
IL8 inhibitors
|
|
US5707622A
(en)
|
1994-03-03 |
1998-01-13 |
Genentech, Inc. |
Methods for treating ulcerative colitis
|
|
US5874080A
(en)
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
|
BR9507545A
(pt)
|
1994-04-28 |
1997-08-05 |
Music Vending Inc |
Sistema de venda de música
|
|
ATE340590T1
(de)
|
1994-07-13 |
2006-10-15 |
Chugai Pharmaceutical Co Ltd |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
US5707621A
(en)
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
EP0806962A4
(en)
|
1995-01-23 |
2001-01-10 |
Univ California |
Methods for the treatment of acid aspiration-induced acute lung injury
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
AU2576697A
(en)
|
1996-04-19 |
1997-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
|
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
|
CA2254782A1
(en)
|
1996-06-26 |
1997-12-31 |
Kenji Yokoi |
Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
|
|
AU3048797A
(en)
|
1996-10-22 |
1998-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Sepsis remedy comprising anti-il-8 antibody as active ingredient
|
|
CA2281794A1
(en)
|
1997-02-21 |
1998-08-27 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
|
|
CN1068524C
(zh)
|
1997-06-23 |
2001-07-18 |
叶庆炜 |
一种治疗顽症牛皮癣的药物
|
|
WO1999037779A1
(en)
|
1998-01-22 |
1999-07-29 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US6419934B1
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
|
US6423321B2
(en)
|
1999-02-24 |
2002-07-23 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of sensorineural hearing loss
|
|
US6015557A
(en)
|
1999-02-24 |
2000-01-18 |
Tobinick; Edward L. |
Tumor necrosis factor antagonists for the treatment of neurological disorders
|
|
IL129180A0
(en)
|
1999-03-25 |
2000-02-17 |
Technion Res & Dev Foundation |
Method and pharmaceutical composition for wound healing
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
MXPA02001878A
(es)
|
1999-08-23 |
2003-08-20 |
Dana Farber Cancer Inst Inc |
Moleculas b7-4 novedosas y usos de las mismas.
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
|
DE19952622A1
(de)
|
1999-11-02 |
2001-05-10 |
Bayer Ag |
Verfahren zur Herstellung von rekombinantem Interleukin-8 und Interleukin-8 Muteinen
|
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
|
US6420346B1
(en)
|
2000-02-07 |
2002-07-16 |
Rappaport Family Institute For Research In The Medical Sciences |
Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
|
|
AR030753A1
(es)
|
2000-09-25 |
2003-09-03 |
Smithkline Beecham Corp |
Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
AU2002246632B2
(en)
|
2000-12-08 |
2007-04-05 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
|
CA2441953A1
(en)
|
2001-03-23 |
2002-10-03 |
The Board Of Regents Of The University Of Texas System |
Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
|
|
CA2475529A1
(en)
|
2002-03-19 |
2003-10-02 |
Abgenix, Inc. |
Methods for treating chronic obstructive pulmonary disease (copd)
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
NZ541050A
(en)
|
2002-12-16 |
2010-06-25 |
Genmab As |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20050142136A1
(en)
|
2003-10-23 |
2005-06-30 |
Lary Suva |
Anti-interleukin 8 therapy for tumor osteolysis
|
|
EA010654B1
(ru)
|
2004-11-23 |
2008-10-30 |
Пи Ай Пи Ко., Лтд. |
Вмонтированная в стену распределительная коробка водоснабжения
|
|
JP4909988B2
(ja)
|
2005-04-20 |
2012-04-04 |
アムジエン・フレモント・インコーポレイテツド |
インターロイキン‐８に対する高親和性の完全ヒトモノクローナル抗体、およびそのような抗体のエピトープ
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
WO2009026117A2
(en)
|
2007-08-16 |
2009-02-26 |
Glaxo Group Limited |
Novel compounds
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US8686119B2
(en)
|
2011-07-24 |
2014-04-01 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
EP2844290A4
(en)
|
2012-05-01 |
2015-12-16 |
Glaxosmithkline Llc |
NOVEL ANTIBODIES
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
TWI612059B
(zh)
|
2013-03-15 |
2018-01-21 |
美國禮來大藥廠 |
泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
|
WO2016044189A1
(en)
*
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
AU2017228470A1
(en)
*
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
MX390955B
(es)
|
2016-06-02 |
2025-03-19 |
Seagen Inc |
Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
|
|
HUE062398T2
(hu)
|
2016-06-02 |
2023-10-28 |
Bristol Myers Squibb Co |
PD-1 blokád nivolumabbal refrakter Hodgkin limfómában
|
|
KR102976378B1
(ko)
*
|
2016-06-03 |
2026-06-11 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
|
WO2019140150A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|